Inactive Instrument

Highlights RepliCel Life Sciences Inc Toronto S.E.

Equities

RP

CA76027P1036

End-of-day quote Toronto S.E. Other stock markets
- ^CAD	-

May. 31	RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 17	RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 30	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	May. 16	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-10-23	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-01	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-29	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-29	CI
RepliCel Life Sciences Inc. Receives Test Results Showing That Cells Injected Through the DermaPrecise	22-08-02	CI
RepliCel Life Sciences Inc. Receives and Analyzes All Data and Images from Independent Laboratory Testing of the Dermaprecise Injector Prototype	22-07-26	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-07-06	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-28	CI
RepliCel Life Sciences Inc. Terminates License Agreement with Shiseido	21-12-21	CI
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-28	CI
RepliCel Life Sciences Inc.’S Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team	21-11-16	CI
Replicel Announces Dermaprecise Trademark for Dermal Injector Product Line	21-10-28	CI
RepliCel Life Sciences Inc. Announces Dermal Injector Update	21-10-27	CI
RepliCel Life Sciences Inc. and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents	21-09-16	CI
Replicel Life Sciences Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies	21-08-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights RepliCel Life Sciences Inc Toronto S.E.

Equities

RP

CA76027P1036

Highlights

Filters